Novanta Inc. (NOVT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 3, 2026. Novanta Inc. is a global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers (OEMs). The company operates through two reportable segments: Automation Enabling Technologies and Medical Solutions.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $257.7 million | $233.4 million |
| Gross Profit | $113.6 million | $104.4 million |
| Gross Margin | 44.1% | 44.7% |
| Operating Income | $27.5 million | $32.4 million |
| Net Income | $21.1 million | $21.2 million |
| Diluted EPS | $0.51 | $0.59 |
| Operating Cash Flow | $51.6 million | $31.7 million |
| Cash & Equivalents | $388.8 million | $106.0 million |
| Total Debt | $241.4 million | $250.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10.4% year-over-year, driven by a 14.8% increase in the Medical Solutions segment (partially due to the Keonn acquisition) and a 6.6% increase in Automation Enabling Technologies. Foreign currency exchange rates favorably impacted revenue by $8.2 million.
- Operating Income Decline: Despite revenue growth, operating income decreased 15.1% to $27.5 million. This was primarily due to an $8.8 million increase in Selling, General, and Administrative (SG&A) expenses and a $5.1 million increase in restructuring and acquisition costs.
- Margin Compression: Gross margin decreased 60 basis points to 44.1%, attributed to higher material costs, increased freight and tariff costs, and temporary costs associated with regionalizing manufacturing.
- EPS Dilution: Diluted EPS decreased to $0.51 from $0.59, primarily due to an increase in weighted average shares outstanding resulting from the prior year's tangible equity unit offering.
Outlook, Risks, and Unusual Items
- Restructuring Programs: The company recorded $2.6 million in restructuring, acquisition, and related costs. The 2025 restructuring program (total expected cost ~$25.0 million) aims to streamline operations and regionalize manufacturing. The 2024 program is expected to be completed by the end of 2026.
- Geopolitical Risks: Management highlighted risks from the conflict involving the U.S., Israel, and Iran (escalated in February 2026), which has increased global energy prices, supply chain uncertainty, and freight costs. Tariffs on imports from China have also contributed to cost increases.
- Capital Allocation: The company completed its $50 million 2020 share repurchase plan and has $191.6 million remaining under its $200 million 2025 Repurchase Plan. It also maintains an $850 million revolving credit facility with no outstanding borrowings as of April 3, 2026.
- Acquisition Integration: The Keonn Technologies acquisition (closed April 2025) contributed $9.2 million in revenue for the quarter but included a pre-tax loss of $0.8 million.
Investor Verification Checklist
- Tariff Impact: Verify the extent to which tariff costs and supply chain disruptions are being passed through to customers versus absorbed in margins.
- Restructuring Execution: Monitor the progress of the 2025 and 2024 restructuring programs to ensure cost savings materialize as projected.
- Geopolitical Exposure: Assess the potential for further escalation in the Middle East conflict and its specific impact on energy and logistics costs.
- Debt Covenants: Confirm continued compliance with the Senior Credit Facilities, specifically the maximum consolidated leverage ratio (currently 0.64 vs. 3.75 limit).
- Medical Segment Growth: Evaluate the sustainability of the 14.8% growth in the Medical Solutions segment, distinguishing between organic growth and acquisition contributions.